1035 CAMBRIDGE STREET, CAMBRIDGE, MA
Investor Presentation
Ernexa Therapeutics Inc. Elects Directors at 2026 Annual Meeting
Annual Report to Security Holders
Ernexa Therapeutics Inc. Implements 1-for-25 Reverse Stock Split
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Pricing of $10.5 Million Public Offering
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Certificate
Registration of Securities
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
Definitive Information Statement
Preliminary Information Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence